ArticleACR open rheumatology2023

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.

Daniel J Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.